Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up
Year: 2020
Type: article
Abstract: not available.
Authors: Danny Rischin, Nikhil Khushalani, Chryslalyne Schmults, Alexander Guminski, Anne Lynn Chang, Karl Lewis, Annette Lim, Leonel Hernandez-Aya, Brett Hughes, Dirk Schadendorf, Axel Hauschild, Elizabeth Stankevich, Jocelyn Booth, Suk-Young Yoo, Zhen Chen, Emmanuel Okoye, Israel Lowy, Matthew Fury, Micahel Migden
Institutions: Peter MacCallum Cancer Centre, Peter MacCallum Cancer Foundation, Moffitt Cancer Center, Brigham and Women's Hospital, Harvard University, Royal North Shore Hospital, Stanford Medicine, Stanford University, University of Colorado Anschutz, University of Colorado Denver, Washington University in St. Louis, The University of Queensland, Royal Brisbane and Women's Hospital, Essen University Hospital, Deutsches Konsortium für Translationale Krebsforschung, University Hospital Schleswig-Holstein, Regeneron (United States), Regenex Pharmaceuticals (China), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Funders: Amgen, Bristol-Myers Squibb, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Array BioPharma, Regeneron Pharmaceuticals, Merck KGaA, Les Laboratories Pierre Fabre, National Comprehensive Cancer Network, Amarin Corporation, Jounce Therapeutics, Incyte, Castle Biosciences, Eisai, Astellas Pharma, Galderma, Sun Pharma, LEO Pharma, Genentech, EMD Serono
OpenAlex ID: W3101227118